Aranesp Phase II Heart Failure Data Suggest Benefit; Phase III Underway
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen presents data from a pooled analysis of two randomized Phase II trials in heart failure patients with anemia.
You may also be interested in...
Amgen And Cytokinetics Partner On Novel Heart Failure Treatments
Deal could be worth more than $725 million.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter